InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (13 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
13
T+90 hit rate
50%
T+90 mean return
+3.5%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Geffner Michael, Chief Medical Officer. Director active across 1 company, notably Immunovant, Inc.. In total, 15 filings have been recorded. Breakdown: 0 buy · 13 sells. Total volume traded: €931k. History available since 26 January 2024. The latest transaction was disclosed on 22 October 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations15 total
2,595 shares@ US$19.0327.5% of flowCommon StockSEC:0001764013-25-000144
2,595 shares@ US$19.030.0008% mcap27.5% of flowCommon StockSEC:0001764013-25-000144:0
1,272 shares@ US$16.3011.5% of flowCommon StockSEC:0001764013-25-000140
1,272 shares@ US$16.300.0003% mcap11.5% of flowCommon StockSEC:0001764013-25-000140:0
1,160 shares@ US$17.2411.0% of flowCommon StockSEC:0001764013-25-000109
1,160 shares@ US$17.240.0003% mcap11.0% of flowCommon StockSEC:0001764013-25-000109:0
2,349 shares@ US$14.793.3% of flowCommon StockSEC:0001764013-25-000082:0
6,169 shares@ US$12.997.9% of flowCommon StockSEC:0001764013-25-000068:0
101,574 shares0Common StockSEC:0001764013-25-000053:0
2,657 shares@ US$23.596.5% of flowCommon StockSEC:0001764013-25-000018:0
3,189 shares@ US$29.539.4% of flowCommon StockSEC:0001764013-24-000179:0
3,456 shares@ US$27.769.5% of flowCommon StockSEC:0001764013-24-000142:0
3,261 shares@ US$28.909.5% of flowCommon StockSEC:0001764013-24-000089:0
54,978 shares0Common StockSEC:0001764013-24-000050:0
9,948 shares@ US$37.9137.4% of flowCommon StockSEC:0001764013-24-000017:0
15 of 15 declarations
About Geffner Michael
Michael Geffner serves as Chief Medical Officer at Immunovant, Inc. In this role, he is responsible for leading the company's medical and clinical initiatives, ensuring that products and services meet health and safety standards. His medical expertise is essential for the development of innovative treatments.
